相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction The PACMAN-AMI Randomized Clinical Trial
Lorenz Raber et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
ETESIAN: A PHASE 2B STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF AZD8233, A PCSK9-TARGETED ANTISENSE OLIGONUCLEOTIDE, IN PATIENTS WITH DYSLIPIDEMIA
Michael J. Koren et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2022)
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction
Stephen J. Nicholls et al.
JACC-CARDIOVASCULAR IMAGING (2022)
Pleiotropic Effects of PCSK9: Focus on Thrombosis and Haemostasis
Marianna Puccini et al.
METABOLITES (2022)
Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis
Paul Guedeney et al.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)
Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial
Gregory G. Schwartz et al.
CIRCULATION (2021)
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
R. Scott Wright et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Proprotein Convertase Subtilisin/Kexin Type 9 A View beyond the Canonical Cholesterol-Lowering Impact
Chiara Macchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2021)
Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins
Bruce A. Warden et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2021)
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Kiran Musunuru et al.
NATURE (2021)
An oral antisense oligonucleotide for PCSK9 inhibition
Peter Gennemark et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
RNA Silencing in the Management of Dyslipidemias
Neil C. Henney et al.
CURRENT ATHEROSCLEROSIS REPORTS (2021)
PCSK9 vaccine: so near, yet so far!
Amirhossein Sahebkar et al.
EUROPEAN HEART JOURNAL (2021)
EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study
Kausik K. Ray et al.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
PCSK9 Inhibitors' New Users: Analysis of Prescription Patterns and Patients' Characteristics from an Italian Real-world Study
Carlo Piccinni et al.
CLINICAL DRUG INVESTIGATION (2020)
A Meta-Analysis of Cardiovascular Outcomes in Patients With Hypercholesterolemia Treated With Inclisiran
Abdul Aziz A. Asbeutah et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia The ORION-2 Pilot Study
G. Kees Hovingh et al.
CIRCULATION (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
New Pharmacological Approaches to Target PCSK9
Alberico L. Catapano et al.
CURRENT ATHEROSCLEROSIS REPORTS (2020)
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies
Julia Brandts et al.
CURRENT OPINION IN LIPIDOLOGY (2020)
The Evolving Understanding and Approach to Residual Cardiovascular Risk Management
Devinder S. Dhindsa et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2020)
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial
Dirk J. Blom et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Low-density Lipoprotein-Cholesterol Lowering Strategies for Prevention of Atherosclerotic Cardiovascular Disease: Focus on siRNA Treatment Targeting PCSK9 (Inclisiran)
David Sinning et al.
CURRENT CARDIOLOGY REPORTS (2020)
Estimation of the major cardiovascular events prevention with Inclisiran
Alberto Cordero et al.
ATHEROSCLEROSIS (2020)
Meta-Analysis of Inclisiran for the Treatment of Hypercholesterolemia
Sajjad A. Khan et al.
AMERICAN JOURNAL OF CARDIOLOGY (2020)
Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
Guy De Backer et al.
ATHEROSCLEROSIS (2019)
PCSK9 Inhibition: New Treatment Options and Perspectives to Lower Atherogenic Lipoprotein Particles and Cardiovascular Risk
Julia Brandts et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
SAFETY, TOLERABILITY AND LDL-C REDUCTION WITH A NOVEL ANTI-PCSK9 RECOMBINANT FUSION PROTEIN (LIB003): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY
E. Stein et al.
ATHEROSCLEROSIS (2019)
Pharmacokinetics and exploratory efficacy biomarkers of bococizumab, an anti-PCSK9 monoclonal antibody, in hypercholesterolemic Japanese subjects
Koutaro Yokote et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2019)
Atherosclerosis
Peter Libby et al.
NATURE REVIEWS DISEASE PRIMERS (2019)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Nabil G. Seidah et al.
CARDIOVASCULAR RESEARCH (2019)
Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab An Analysis of FOURIER Trial Data
Arman Qamar et al.
JAMA CARDIOLOGY (2019)
Diagnosing Resistance to a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
Michael D. Shapiro et al.
ANNALS OF INTERNAL MEDICINE (2018)
Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials
Harold E. Bays et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins Prespecified Secondary End Points in ORION 1
Kausik K. Ray et al.
CIRCULATION (2018)
Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
Jalpa A. Doshi et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)
Prior Authorization Requirements for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Across US Private and Public Payers
Jalpa A. Doshi et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Dionne M. Hines et al.
VASCULAR HEALTH AND RISK MANAGEMENT (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
Kevin Fitzgerald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients
P. M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia
Peter P. Toth et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Effects of RG7652, a Monoclonal Antibody Against PCSK9, on LDL-C, LDL-C Subtractions, and Inflammatory Biomarkers in Patients at High Risk of or With Established Coronary Heart Disease (from the Phase 2 EQUATOR Study)
Amos Baruch et al.
AMERICAN JOURNAL OF CARDIOLOGY (2017)
On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects
Hagai Tavori et al.
ATHEROSCLEROSIS (2015)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2015)
Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society
Marina Cuchel et al.
EUROPEAN HEART JOURNAL (2014)
Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia
Evan A. Stein et al.
CIRCULATION (2013)
An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes
Liwen Zhang et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population
Amanda J. Hooper et al.
ATHEROSCLEROSIS (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9
S Rashid et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
